ABL1 and acute lymphoblastic leukemia: Measurable Residual Disease (MRD) was performed by multiparameter flow cytometry (4-6 color assay) in Philadelphia chromosome-negative (Ph-) ALL and quantitative polymerase chain reaction in Ph+ ALL, BCR-ABL1 mRNA transcripts.